Statistics for A Phase 2 Study of Dasatinib in Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum or Endometrium: NRG Oncology/Gynecologic Oncology Group Study 0283
Total visits
| views | |
|---|---|
| A Phase 2 Study of Dasatinib in Recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum or Endometrium: NRG Oncology/Gynecologic Oncology Group Study 0283 | 7 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 5 |
| February 2025 | 2 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:83e53f54-6e7d-4e60-a187-8ef6f334b0e2 | 80 |
| java.util.UUID:4fd15c17-a80a-4b94-97a9-d2c7f10f5503 | 33 |
| OCearbhaill2023Phase2-AAM.pdf | 13 |
| java.util.UUID:1ad53d14-a051-43ba-9581-f67f455e170d | 3 |